Results 41 to 50 of about 484,175 (264)

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Redefining the pharmacology and pharmacy subject category in the journal citation reports using medical subject headings (MeSH) [PDF]

open access: yes, 2017
© 2017, Springer International Publishing AG. Background The Journal Citation Reports (JCR) Pharmacology and Pharmacy subject category is heterogeneous.
Salgado, TM   +7 more
core   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

open access: yesMolecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober   +16 more
wiley   +1 more source

Joint-Effort Clinical Pharmacy Services in Rural Hospitals [PDF]

open access: yes, 2008
Studies in the literature support the practice of having clinical pharmacists work in direct patient care and the value of these services within the health care system.1,2 Although most pharmacists want to provide pharmaceutical care in collaboration ...
Totton, Joyce, Hunt, Pat, Pritchard, Kim
core   +2 more sources

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

open access: yesMolecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi   +11 more
wiley   +1 more source

Reflecting on patient-centred care in pharmacy through an illness narrative: [PDF]

open access: yes, 2015
Patient-centred care (PCC) is rapidly adopting a central position in discussions on the quality of healthcare, with patient-centredness deemed essential to transforming the healthcare system.
Dowse, Roslind
core   +1 more source

Establishing an assay to evaluate d‐amino acid oxidase enzyme kinetics and inhibition using WST‐8 redox dye

open access: yesFEBS Open Bio, EarlyView.
This study investigated a novel WST‐8‐based assay for evaluating d‐Amino acid oxidase (DAO) inhibitors. We confirmed its effectiveness using known inhibitors and found that uremic toxins possess relatively weak inhibitory activity compared to existing drugs.
Kahoko Miyake   +4 more
wiley   +1 more source

Factors influencing pharmacists' clinical decision making in pharmacy practice [PDF]

open access: yes, 2023
BACKGROUND: Pharmacists' clinical decision-making is considered a core process of pharmaceutical care in pharmacy practice, but little is known about the factors influencing this process.
Bouvy, M L   +4 more
core  

Screening and epitope characterization of Nidogen‐2‐specific nanobodies

open access: yesFEBS Open Bio, EarlyView.
Camel immunization and phage display were employed to generate high‐affinity VHH nanobodies against Nidogen‐2. After library construction, biopanning, ELISA screening, sequencing, and recombinant expression, selected nanobodies were purified and characterized, leading to the preliminary exploration of a nanobody‐based sandwich ELISA for specific ...
Jianchuan Wen   +9 more
wiley   +1 more source

Community pharmacy wider roles project [PDF]

open access: yes, 1999
In 1996 the NHS Executive’s Pharmaceutical and Optical Branch invited health authority bids to carry out pilots testing some form of extended role for community pharmacy. In 1997 it funded twelve pilots.
Woodward, J.   +6 more
core  

Home - About - Disclaimer - Privacy